CAMP4 Therapeutics (NASDAQ:CAMP) Raised to Overweight at JPMorgan Chase & Co.

CAMP4 Therapeutics (NASDAQ:CAMP) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Tuesday,Benzinga reports. The firm currently has a $9.00 price target on the Wireless communications provider’s stock, up from their previous price target of $5.00. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 127.27% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Weiss Ratings cut CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 21st. Leerink Partners raised their target price on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CAMP4 Therapeutics in a report on Friday, March 6th. Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 10th. Finally, Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, CAMP4 Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $8.36.

CAMP4 Therapeutics Stock Performance

Shares of CAMP4 Therapeutics stock opened at $3.96 on Tuesday. CAMP4 Therapeutics has a one year low of $1.30 and a one year high of $7.75. The stock’s fifty day moving average is $4.35 and its 200 day moving average is $4.70. The stock has a market cap of $205.64 million, a P/E ratio of -1.68 and a beta of 0.08.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%.The company had revenue of $1.29 million during the quarter. Analysts predict that CAMP4 Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On CAMP4 Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $61,000. Jefferies Financial Group Inc. bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $70,000. State Street Corp raised its holdings in CAMP4 Therapeutics by 52.7% during the fourth quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider’s stock valued at $243,000 after acquiring an additional 13,700 shares during the period. Bank of America Corp DE bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $86,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in CAMP4 Therapeutics during the fourth quarter valued at about $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.